Biotech Values

[genisi]

Cambrex knew as early as Oct. 2002, that it lost the TKT contract as a result of FDA concerns with TKT's Replagal application (Replagal failed to improve kidney function in patients with Fabry disease), and that caused CBM's share to lose more than one third of its value on early Oct. 2002.